PAP
RIGL icon

Persistent Asset Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Persistent Asset Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
+5,821
New +$180K 0.07% 198
2026
Q1 		– Sell
-7,995
Closed -$342K – 450
2025
Q4 		$342K Buy
+7,995
New +$301K 0.15% 169

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Persistent Asset Partners's RIGL Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 5,821 shares worth $228K. The stake represents 0.07% of the portfolio and ranks #198 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in RIGL as recently as Q4 2025.

Persistent Asset Partners first reported a position in RIGL in Q4 2025 and has held it in 2 quarters since. The position peaked at $342K in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Persistent Asset Partners held 5,821 shares of Rigel Pharmaceuticals worth $228K as of Q2 2026.
  • Rigel Pharmaceuticals was a new Persistent Asset Partners position in Q2 2026.
  • Rigel Pharmaceuticals made up 0.07% of Persistent Asset Partners's portfolio in Q2 2026, its #198 holding.
  • Persistent Asset Partners first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Rigel Pharmaceuticals position peaked at $342K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.